Clinical trial · Interventional
Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was stopped because of lack of funding.
Summary
Brief summary (as posted)
The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epoetin Alfa plus Iron | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Epoetin Alfa plus Iron
- interventionNames
- Drug: Epoetin Alfa plus Iron
Primary outcomes (1)
- measure
- Achieve hemoglobin responses > 2g/dl in at least 70% of patients
- timeFrame
- Nine weeks, after at least two doses of 120,000 units epoetin alfa
Secondary outcomes (1)
- measure
- Descriptive evaluation of adverse effects of parenteral iron and epoetin alfa 120,000 units given every three weeks
- timeFrame
- Patient follow up until week 12
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed small cell or non small cell lung cancer * Stage III or Stage IV lung cancer * Platinum containing chemotherapy induced anemia (\< 10 g/dl Hb) * Cancer related anemia (\<10 g/dl Hb) at time of initiation of chemotherapy * ECOG performance status of 0,1, or 2 * Informed consent * Age\>18 * Expected to receive platinum based outpatient chemotherapy for at least nine weeks Exclusion Criteria: * Pregnant women * Intolerance to epoetin alfa or parenteral iron * More than 2 cycles of the planned platinum chemotherapy at time of enrollment * Chronic GI bleed (\> than 4 weeks positive hemoccult or gastroccult) * Ferritin \> 500 mg/dl * Anemia due to other causes than cancer or chemotherapy * Previous parenteral iron therapy * Uncontrolled hypertension (systolic BP \> 160, diastolic \> 100 mmHg)
References
Publications (0)
Data not yet available